epocrates
Drug Updates: Week of February 23, 2026
Here's a quick roundup of last week’s new drug monographs and updates.
New Brand Monograph
- Indications: 1) chemo-induced febrile neutropenia prophylaxis in adult and pediatric patients ≥7 months; 2) post-BMT neutropenia in adult and pediatric patients ≥7 months; 3) severe chronic neutropenia in adult and pediatric patients ≥7 months; and 4) various other
- Formulation: subcutaneous or intravenous injection
New and Expanded Indications
Darzalex Faspro (daratumumab/hyaluronidase-fihj)
- New: newly diagnosed multiple myeloma - combo w/ bortezomib, lenalidomide, dexamethasone, autologous HSCT ineligible adult patients
- Existing: newly diagnosed multiple myeloma - various
- Read more: Darzalex Faspro combo OK’d for newly diagnosed multiple myeloma
Formulation Updates
- Added new tablet strength: TAB: 1000 mg
- Added injectable form: KwikPen pen in various concentrations
- Added new tablet form: TAB: 1.5 mg, 4 mg, 9 mg
- Added injectable form administered via IV infusion
- Added new pack: TAB (80 mg once weekly pack): 80 mg x4
- Added injectable forms: KwikPen pen and additional concentrations available in vial
First-time Generic
ciprofloxacin/hydrocortisone otic
- Indications: acute bacterial otitis externa in adult and pediatric patients ≥1 year
- Equivalent brand: Cipro HC
Investigational New Drugs (IND)
- Proposed indications: fibrodysplasia ossificans progressiva
- Status: pending FDA approval
- Proposed indications: relapsed or refractory multiple myeloma
- Status: pending FDA approval
- Proposed indications: relapsed or refractory multiple myeloma; primary CNS lymphoma
- Status: pending FDA approval